1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Paracetamol Solution for Infusion
Trade Name: Paracetamol IV Pfizer
Synonyms: Paracetamol IV
Chemical Family: Not determined

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as analgesic

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification: Not classified as hazardous
EU Classification:
EU Indication of danger: Not classified

Label Elements

Other Hazards: No data available
Australian Hazard Classification (NOHSC):

Note:
This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.
### 3. COMPOSITION / INFORMATION ON INGREDIENTS

#### Hazardous

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetaminophen (paracetamol)</td>
<td>103-90-2</td>
<td>203-157-5</td>
<td>Not Listed</td>
<td>Acute Tox.5 (H303)</td>
<td>1</td>
</tr>
<tr>
<td>Acetic acid</td>
<td>64-19-7</td>
<td>200-580-7</td>
<td>R10 C; R35</td>
<td>Skin Corr. 1A (H314) Flam. Liq. 3 (H226)</td>
<td>&lt;0.1</td>
</tr>
<tr>
<td>HYDROCHLORIC ACID</td>
<td>7647-01-0</td>
<td>231-595-7</td>
<td>T; R23 C; R35</td>
<td>Skin Corr.1B (H314) STOT SE 3 (H335)</td>
<td>**</td>
</tr>
<tr>
<td>SODIUM HYDROXIDE</td>
<td>1310-73-2</td>
<td>215-185-5</td>
<td>C; R35</td>
<td>Skin Corr. 1A (H314)</td>
<td>**</td>
</tr>
</tbody>
</table>

**Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.**

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Water for Injection</td>
<td>7732-18-5</td>
<td>231-791-2</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Glucose</td>
<td>50-99-7</td>
<td>200-075-1</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Sodium citrate, dihydrate</td>
<td>6132-04-3</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Sodium acetate trihydrate</td>
<td>6131-90-4</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

**Additional Information:**

* Proprietary
** to adjust pH

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

### 4. FIRST AID MEASURES

#### Description of First Aid Measures

**Eye Contact:**
Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

**Skin Contact:**
Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

**Ingestion:**
Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

**Inhalation:**
Remove to fresh air and keep patient at rest. Seek medical attention immediately.

#### Most Important Symptoms and Effects, Both Acute and Delayed

**Symptoms and Effects of Exposure:**
For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

**Medical Conditions Aggravated by Exposure:**
None known

#### Indication of the Immediate Medical Attention and Special Treatment Needed

**Notes to Physician:** None
5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion: Formation of toxic gases is possible during heating or fire. May include oxides of carbon and products of nitrogen.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of the spill if it is safe to do so. Absorb spills with non-combustible absorbent material and transfer into a labeled container for disposal. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Acetaminophen (paracetamol)

Pfizer OEL TWA-8 Hr: 3 mg/m³
Ireland OEL - TWAs 10 mg/m³

Acetic acid

ACGIH Threshold Limit Value (TWA) 10 ppm
ACGIH Threshold Limit Value (STEL) 15 ppm
Australia STEL 37 mg/m³
## 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

<table>
<thead>
<tr>
<th>Country</th>
<th>Twas (ppm)</th>
<th>Twa (mg/m³)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia</td>
<td>10</td>
<td>25</td>
</tr>
<tr>
<td>Austria OEL - MAKs</td>
<td>10</td>
<td>25</td>
</tr>
<tr>
<td>Belgium OEL - TWA</td>
<td>10</td>
<td>25</td>
</tr>
<tr>
<td>Bulgaria OEL - TWA</td>
<td>25.0</td>
<td>25</td>
</tr>
<tr>
<td>Cyprus OEL - TWA</td>
<td>10</td>
<td>25</td>
</tr>
<tr>
<td>Czech Republic OEL - TWA</td>
<td>25</td>
<td>25</td>
</tr>
<tr>
<td>Denmark OEL - TWA</td>
<td>10</td>
<td>25</td>
</tr>
<tr>
<td>Estonia OEL - TWA</td>
<td>10</td>
<td>25</td>
</tr>
<tr>
<td>Finland OEL - TWA</td>
<td>5</td>
<td>13</td>
</tr>
<tr>
<td>Germany - TRGS 900 - TWAs</td>
<td>10</td>
<td>25</td>
</tr>
<tr>
<td>Germany (DFG) - MAK</td>
<td>10</td>
<td>25</td>
</tr>
<tr>
<td>Greece OEL - TWA</td>
<td>10</td>
<td>25</td>
</tr>
<tr>
<td>Hungary OEL - TWA</td>
<td>25</td>
<td>25</td>
</tr>
<tr>
<td>Ireland OEL - TWAs</td>
<td>10</td>
<td>25</td>
</tr>
<tr>
<td>Latvia OEL - TWA</td>
<td>10</td>
<td>25</td>
</tr>
<tr>
<td>Lithuania OEL - TWA</td>
<td>10</td>
<td>25</td>
</tr>
<tr>
<td>Luxembourg OEL - TWA</td>
<td>10</td>
<td>25</td>
</tr>
<tr>
<td>Malta OEL - TWA</td>
<td>10</td>
<td>25</td>
</tr>
<tr>
<td>OSHA - Final PELS - TWAs</td>
<td>10</td>
<td>25</td>
</tr>
<tr>
<td>Poland OEL - TWA</td>
<td>15</td>
<td>25</td>
</tr>
<tr>
<td>Portugal OEL - TWA</td>
<td>10</td>
<td>25</td>
</tr>
<tr>
<td>Romania OEL - TWA</td>
<td>10</td>
<td>25</td>
</tr>
<tr>
<td>Slovakia OEL - TWA</td>
<td>10</td>
<td>25</td>
</tr>
<tr>
<td>Slovenia OEL - TWA</td>
<td>10</td>
<td>25</td>
</tr>
<tr>
<td>Spain OEL - TWA</td>
<td>10</td>
<td>25</td>
</tr>
<tr>
<td>Sweden OEL - TWAs</td>
<td>5</td>
<td>13</td>
</tr>
<tr>
<td>Switzerland OEL - TWAs</td>
<td>10</td>
<td>25</td>
</tr>
<tr>
<td>Vietnam OEL - TWAs</td>
<td>25</td>
<td></td>
</tr>
</tbody>
</table>

**HYDROCHLORIC ACID**

ACGIH Ceiling Threshold Limit: 2 ppm
### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

<table>
<thead>
<tr>
<th>Country/Region</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia PEAK</td>
<td>5 ppm, 7.5 mg/m³</td>
</tr>
<tr>
<td>Austria OEL - MAKs</td>
<td>5 ppm, 8 mg/m³</td>
</tr>
<tr>
<td>Belgium OEL - TWA</td>
<td>5 ppm, 8 mg/m³</td>
</tr>
<tr>
<td>Bulgaria OEL - TWA</td>
<td>5 ppm, 8.0 mg/m³</td>
</tr>
<tr>
<td>Cyprus OEL - TWA</td>
<td>5 ppm, 8 mg/m³</td>
</tr>
<tr>
<td>Czech Republic OEL - TWA</td>
<td>8 mg/m³</td>
</tr>
<tr>
<td>Estonia OEL - TWA</td>
<td>5 ppm, 8 mg/m³</td>
</tr>
<tr>
<td>Germany - TRGS 900 - TWAs</td>
<td>2 ppm, 3 mg/m³</td>
</tr>
<tr>
<td>Germany (DFG) - MAK</td>
<td>2 ppm, 3.0 mg/m³</td>
</tr>
<tr>
<td>Greece OEL - TWA</td>
<td>5 ppm, 7 mg/m³</td>
</tr>
<tr>
<td>Hungary OEL - TWA</td>
<td>8 mg/m³</td>
</tr>
<tr>
<td>Ireland OEL - TWAs</td>
<td>5 ppm, 8 mg/m³</td>
</tr>
<tr>
<td>Italy OEL - TWA</td>
<td>5 ppm, 8 mg/m³</td>
</tr>
<tr>
<td>Japan - OELs - Ceilings</td>
<td>5 ppm, 7.5 mg/m³</td>
</tr>
<tr>
<td>Latvia OEL - TWA</td>
<td>5 ppm, 8 mg/m³</td>
</tr>
<tr>
<td>Lithuania OEL - TWA</td>
<td>5 ppm, 8 mg/m³</td>
</tr>
<tr>
<td>Luxembourg OEL - TWA</td>
<td>5 ppm, 8 mg/m³</td>
</tr>
<tr>
<td>Malta OEL - TWA</td>
<td>5 ppm, 8 mg/m³</td>
</tr>
<tr>
<td>Netherlands OEL - TWA</td>
<td>8 mg/m³</td>
</tr>
<tr>
<td>Poland OEL - TWA</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>Romania OEL - TWA</td>
<td>5 ppm, 8 mg/m³</td>
</tr>
<tr>
<td>Slovakia OEL - TWA</td>
<td>5 ppm, 8.0 mg/m³</td>
</tr>
<tr>
<td>Slovenia OEL - TWA</td>
<td>5 ppm, 8 mg/m³</td>
</tr>
<tr>
<td>Spain OEL - TWA</td>
<td>5 ppm, 7.6 mg/m³</td>
</tr>
<tr>
<td>Switzerland OEL - TWAs</td>
<td>2 ppm, 3.0 mg/m³</td>
</tr>
<tr>
<td>Vietnam OEL - TWAs</td>
<td>5 mg/m³</td>
</tr>
</tbody>
</table>

### SODIUM HYDROXIDE

- **ACGIH Ceiling Threshold Limit:** 2 mg/m³
- **Australia PEAK:** 2 mg/m³
- **Austria OEL - MAKs:** 2 mg/m³
- **Bulgaria OEL - TWA:** 2.0 mg/m³
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

**Exposure Controls**

**Engineering Controls:** Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

**Personal Protective Equipment:** Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

**Hands:** Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

**Eyes:** Wear safety glasses or goggles if eye contact is possible.

**Skin:** Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

**Respiratory protection:** If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

**Physical State:** Solution

**Odor:** Odorless

**Molecular Formula:** C8 H9 N O2

**Color:** No data available.

**Odor Threshold:** No data available.

**Molecular Weight:** 151.2

**Solvent Solubility:** Soluble: Alcohol

**Water Solubility:** No data available

**Solubility:** Water Slightly Soluble:

**pH:** No data available.

**Melting/Freezing Point (°C):** No data available

**Boiling Point (°C):** No data available

**Partition Coefficient: (Method, pH, Endpoint, Value)**

**Acetaminophen (paracetamol)**

No data available

**Glucose**

No data available

**Sodium acetate trihydrate**

No data available

**Sodium citrate, dihydrate**

No data available

**Water for Injection**

No data available
9. PHYSICAL AND CHEMICAL PROPERTIES

**HYDROCHLORIC ACID**
No data available

**SODIUM HYDROXIDE**
No data available

**Acetic acid**
No data available

**Decomposition Temperature (°C):** No data available.

**Evaporation Rate (Gram/s):** No data available
**Vapor Pressure (kPa):** No data available
**Vapor Density (g/ml):** No data available
**Relative Density:** No data available
**Viscosity:** No data available

**Flammability:**
- **Autoignition Temperature (Solid) (°C):** No data available
- **Flammability (Solids):** No data available
- **Flash Point (Liquid) (°C):** No data available
- **Upper Explosive Limits (Liquid) (% by Vol.):** No data available
- **Lower Explosive Limits (Liquid) (% by Vol.):** No data available
- **Polymerization:** Will not occur

10. STABILITY AND REACTIVITY

**Reactivity:** No data available

**Chemical Stability:** Stable under normal conditions of use.

**Possibility of Hazardous Reactions**

**Oxidizing Properties:** No data available

**Conditions to Avoid:** Fine particles (such as dust and mists) may fuel fires/explosions. As a precautionary measure, keep away from heat sources and electrostatic discharge.

**Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers

**Hazardous Decomposition Products:** No data available

11. TOXICOLOGICAL INFORMATION

**Information on Toxicological Effects**

**Long Term:** Acute overdosage of acetaminophen can cause liver damage. Chronic abuse may result in kidney effects.

**Known Clinical Effects:** Adverse effects associated with therapeutic use of acetaminophen include skin rash and gastrointestinal disturbances. Cases of severe overdose may lead to liver effects kidney effects. Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions. Acetaminophen has been associated with a risk of rare but serious skin reactions. These skin reactions, known as Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP), can be fatal.

**Acute Toxicity: (Species, Route, End Point, Dose)**

Acetaminophen (paracetamol)
- **Rat** Oral LD50 2404 mg/kg
- **Mouse** Oral LD50 338mg/kg

Glucose

PZ02462
11. TOXICOLOGICAL INFORMATION

Hydrochloric Acid
Rat Oral LD50 238-277 mg/kg

Acetic Acid
Rat Oral LD50 3530 mg/kg
Mouse Inhalation LC50 5000 ppm

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Acetaminophen (paracetamol)
60 Day(s) Rat Oral 600 mg/kg/day LOAEL Kidney
13 Week(s) Mouse Oral 3200 ppm NOEL Liver
13 Week(s) Rat Oral 6200 ppm NOEL Liver, Kidney, Reproductive system, Lymphoid tissue, Thymus
200 Day(s) Rat Oral 200 mg/kg/day NOAEL None identified

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Acetaminophen (paracetamol)
2 Generation Reproductive Toxicity Mouse Oral 0.25 % NOEL Neonatal toxicity
Reproductive & Fertility Mouse Oral 0.1 % LOEL Not Teratogenic, Fertility, Neonatal mortality
Embryo / Fetal Development Rat Oral 250 mg/kg NOEL Not Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Acetaminophen (paracetamol)
Bacterial Mutagenicity (Ames) Salmonella Negative
Chromosome Aberration Chinese Hamster Ovary (CHO) cells Positive
Sister Chromatid Exchange Chinese Hamster Ovary (CHO) cells Positive

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Acetaminophen (paracetamol)
104 Week(s) Rat Female Oral, in feed 600 ppm LOEL Malignant tumors, Blood
104 Week(s) Rat Male Oral, in feed 6000 ppm NOEL Not carcinogenic
104 Week(s) Mouse Oral, in feed 6000 ppm NOEL Not carcinogenic

Carcinogen Status:
None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

Acetaminophen (paracetamol)
IARC: Group 3 (Not Classifiable)

Hydrochloric Acid
IARC: Group 3 (Not Classifiable)
12. ECOLOGICAL INFORMATION

Environmental Overview: The environmental characteristics of this material have not been fully evaluated. Releases to the environment should be avoided.

Toxicity:
Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Acetic acid
- *Pimephales promelas* (Fathead Minnow) LC-50 1 Hours > 315 mg/L
- *Pimephales promelas* (Fathead Minnow) LC-50 24 Hours 122 mg/L
- *Mysidopsis bahia* (Mysid Shrimp) LC-50 48 Hours 100-300 mg/L

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications

WHMIS hazard class: None required

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.
15. REGULATORY INFORMATION

### Water for Injection
- **CERCLA/SARA 313 Emission reporting**: Not Listed
- **California Proposition 65**: Not Listed
- **Inventory - United States TSCA - Sect. 8(b)**: Present
- **Australia (AICS)**: Present
- **REACH - Annex IV - Exemptions from the obligations of Register**: Present
- **EU EINECS/ELINCS List**: 231-791-2

### Glucose
- **CERCLA/SARA 313 Emission reporting**: Not Listed
- **California Proposition 65**: Not Listed
- **Inventory - United States TSCA - Sect. 8(b)**: Present
- **Australia (AICS)**: Present
- **REACH - Annex IV - Exemptions from the obligations of Register**: Present
- **EU EINECS/ELINCS List**: 200-075-1

### Acetaminophen (paracetamol)
- **CERCLA/SARA 313 Emission reporting**: Not Listed
- **California Proposition 65**: Not Listed
- **Inventory - United States TSCA - Sect. 8(b)**: Present
- **Australia (AICS)**: Present
- **Standard for the Uniform Scheduling for Drugs and Poisons**: Schedule 2, Schedule 3, Schedule 4
- **EU EINECS/ELINCS List**: 203-157-5

### Sodium citrate, dihydrate
- **CERCLA/SARA 313 Emission reporting**: Not Listed
- **California Proposition 65**: Not Listed
- **Australia (AICS)**: Present
- **EU EINECS/ELINCS List**: Not Listed

### Sodium acetate trihydrate
- **CERCLA/SARA 313 Emission reporting**: Not Listed
- **California Proposition 65**: Not Listed
- **Australia (AICS)**: Present
- **EU EINECS/ELINCS List**: Not Listed

### Acetic acid
- **CERCLA/SARA 313 Emission reporting**: Not Listed
- **CERCLA/SARA Hazardous Substances and their Reportable Quantities**: 5000 lb, 2270 kg
15. REGULATORY INFORMATION

California Proposition 65: Not Listed
Inventory - United States TSCA - Sect. 8(b): Present
Australia (AICS): Present
Standard for the Uniform Scheduling for Drugs and Poisons:
Schedule 2
Schedule 5
Schedule 6

EU EINECS/ELINCS List: 200-580-7

HYDROCHLORIC ACID

CERCLA/SARA 313 Emission reporting: 1.0 %
CERCLA/SARA Hazardous Substances and their Reportable Quantities:
5000 lb
2270 kg
CERCLA/SARA - Section 302 Extremely Hazardous TPQs:
500 lb
CERCLA/SARA - Section 302 Extremely Hazardous Substances EPCRA RQs:
California Proposition 65: Not Listed
Inventory - United States TSCA - Sect. 8(b): Present
Australia (AICS): Present
Standard for the Uniform Scheduling for Drugs and Poisons:
Schedule 5
Schedule 6
EU EINECS/ELINCS List: 231-595-7

SODIUM HYDROXIDE

CERCLA/SARA 313 Emission reporting: Not Listed
CERCLA/SARA Hazardous Substances and their Reportable Quantities:
1000 lb
454 kg
California Proposition 65: Not Listed
Inventory - United States TSCA - Sect. 8(b): Present
Australia (AICS): Present
Standard for the Uniform Scheduling for Drugs and Poisons:
Schedule 5
Schedule 6
EU EINECS/ELINCS List: 215-185-5

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.5; H303 - May be harmful if swallowed
Skin corrosion/irritation-Cat.1A; Skin corrosion/irritation-Cat.1B; H314 - Causes severe skin burns and eye damage
Specific target organ toxicity, single exposure; Narcotic effects-Cat.3; H335 - May cause respiratory irritation
Flammable liquids-Cat.3; H226 - Flammable liquid and vapor

T - Toxic
C - Corrosive
R23 - Toxic by inhalation.
R35 - Causes severe burns.
R10 - Flammable.

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Revision date: 28-Oct-2014
End of Safety Data Sheet